The Wall Street Journal logo

Venture Capitalists Fund New Generation of Alzheimer’s Drugs

After years of failure, drugmakers find success with medications for leading cause of dementia

By Brian Gormley
July 13, 2023 6:00 am ET | WSJ Pro

Alzheon, a biotech startup in Framingham, Mass., is developing a drug that blocks the formation of protein aggregates in the brain known as soluble amyloid oligomers, which damage neurons and their connections, according to the company. It expects data from a late-stage study of patients who have two copies of the APOE4 gene, the strongest genetic risk factor for Alzheimer’s, in the third quarter of 2024, CEO Dr. Martin Tolar said.

Read the full article here
Source: wsj.com